PRIMO 2024 | Transformative potential of CAR-T cell therapy: current challenges and future Directions

Manmeet Ahluwalia, MD, MBA, FASCO, Baptist Health Miami Cancer Institute, Kendall, FL, discusses the transformative impact of CAR-T cell therapies in lymphomas, multiple myeloma, and certain leukemias, contrasting their limited efficacy in solid tumors. Looking ahead, he anticipates the next decade will focus on enhancing CAR-T therapies for solid tumors, particularly in reducing the delay between production and infusion, which currently averages 3 to 4 weeks. Prof. Lesser highlights ongoing efforts to develop off-the-shelf CARs for quicker administration and improve management of therapy-related toxicities like cytokine release syndrome and neurotoxicity. He underscores the importance of multidisciplinary teams for optimal patient care. This interview took place at the 2024 PRIMO meeting in Honolulu, Hawaii.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.